Amplitude Inc vs ARK Genomic Revolution ETF — how do they compare? Amplitude Inc trades at $12.43 (market cap $1.59B), while ARK Genomic Revolution ETF trades at $44.34. Which is the better fit depends on your goals.
| AMPL | ARKG | |
|---|---|---|
Market Cap | $1.59B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $12.69 | $44.55 |
52-Week Low | $5.61 | $24.02 |
Enterprise Value | $1.45B | — |
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $12.19, up 8.26% over 24 hours, with strong technical momentum indicated by bullish moving averages. The company shows robust revenue growth, reaching $343.21 million in 2025, but continues to report net losses with a -26.59% margin. Recent news highlights AI-driven growth initiatives and enterprise customer expansion as key catalysts.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, persistent profitability challenges and ongoing legal investigations present significant risks. The stock's current valuation at 4.49x sales appears reasonable given growth prospects, but sustained losses require careful monitoring of margin improvement efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →